stockrowAvalo Therapeutics, Inc. (AVTX) vs Lyell Immunopharma, Inc. (LYEL)
- Avalo Therapeutics, Inc. AVTX 6.95 +4.83%
- Lyell Immunopharma, Inc. LYEL 14.82 −1.20%
Avalo Therapeutics, Inc. and Lyell Immunopharma, Inc. are both Biotechnology companies. Avalo Therapeutics, Inc. and Lyell Immunopharma, Inc. are of similar size ($367.6M and $355.6M). Lyell Immunopharma, Inc. grew revenue faster over the last twelve months: −63.4% against −92.7%. Avalo Therapeutics, Inc. has the higher net margin (0.00% vs −1,701,066.7%) and the higher return on invested capital (−118.2% vs −1,070.8%). Across the 17 metrics below, Avalo Therapeutics, Inc. leads on 14 and Lyell Immunopharma, Inc. on 3.
Valuation
Profitability
| Metric | AVTX | LYEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 64.72% | 100.00% | 68.51% |
| Operating margin | 0.00% | (1,783,580.00%) | 0.00% |
| Net margin | 0.00% | (1,701,066.67%) | 0.00% |
| Free cash flow margin | 0.00% | (928,333.33%) | 0.00% |
| Return on equity | (36.27%) | (97.79%) | (51.96%) |
| Return on assets | (32.50%) | (74.85%) | (46.06%) |
| Return on invested capital | (118.21%) | (1,070.83%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack